ArticleCureus2025
Pregabalin Use in Treatment-Resistant Depression: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin B12 and pregabalin combination restored brain waves dynamics and behavior in chronic unpredictable mild stress (CUMS) model of depression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant depression (TRD) significantly contributes to morbidity and mortality, characterized by persistent depressive symptoms despite comprehensive therapeutic interventions. Standard antidepressants for managing major depressive disorder (MDD) primarily target the serotonin, dopamine, and norepinephrine pathways. Pregabalin, an anxiolytic anticonvulsant, shows promise as an adjunct therapy for TRD. This case report details a 57-year-old male with a 10-year history of MDD who experienced substantial symptom improvement following the addition of pregabalin to his treatment regimen. Previous interventions, including traditional antidepressants, antipsychotics, thyroid supplementation, stimulants, stimulant-like medications, electroconvulsive therapy, and transcranial magnetic stimulation, were either poorly tolerated or ineffective. This case demonstrates pregabalin's potential as an effective adjunct in TRD management and underscores the importance of individualized treatment strategies to optimize outcomes for patients with complex psychiatric and medical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.